Strides Pharma Science Q4 FY26 Results: PAT Rs 129 Cr, Revenue Rs 1,323 Crore
- May 19, 2026
- Posted by: Kashish Aggarwal
- Category: News
Strides Pharma Science Q4 FY26 results were declared on May 18, 2026, at the board of directors meeting. Strides Pharma Science reported PAT of Rs 129 crore for the quarter ended March 31, 2026, up 50.0% YoY from Rs 86 crore in Q4 FY25, on revenue of Rs 1,323 crore. Strides Pharma Science operates in the pharmaceutical formulations and APIs sector. Investors tracking Strides Pharma Science Q4 FY26 will find complete financial analysis and FY27 outlook in this article.
Click Here – Get Free Investment Predictions
Strides Pharma Science Q4 FY26 Financial Highlights
| Metric | Q4 FY26 | Comparison |
|---|---|---|
| PAT (Net Profit) | Rs 129 crore | up 50.0% YoY from Rs 86 crore in Q4 FY25 |
| Revenue from Operations | Rs 1,323 crore | Quarter ended March 31, 2026 |
| Ticker | Sector: Pharmaceuticals |
Strides Pharma Science Q4 FY26 Performance Analysis
Strides Pharma Science Q4 FY26 reflects the company’s operational performance during the January to March 2026 quarter. Strides Pharma Science is a leading pharmaceutical formulations and APIs company whose Q4 FY26 print sets the baseline for FY27 guidance. The profitability improvement demonstrates effective operating leverage and cost management. Q4 January to March is typically a seasonally strong quarter for Indian companies driven by year-end government procurement and project completion cycles.
Investors tracking Strides will monitor FY27 revenue guidance, margin trajectory, and management commentary. Track Strides Pharma Science on the Univest Screener for live data.
Check the Univest Screener for live data
Key Factors for the company
Revenue and Sector Dynamics
Strides revenue of Rs 1,323 crore reflects the company’s execution in the pharmaceutical formulations and APIs space. India’s sustained economic growth of 6.5%+ and robust domestic demand across sectors provide a supportive backdrop for FY27 business planning.
Profitability and Margin Trends
The company PAT of Rs 129 crore up 50.0% YoY from Rs 86 crore in Q4 FY25 demonstrates consistent earnings delivery and improving profitability metrics. Management commentary on FY27 capex and growth investments will guide the stock’s near-term trajectory.
FY27 Business Outlook
Following the firm results, management guidance on FY27 revenue, order book, and strategic priorities will be key catalysts. Download the Univest iOS App or Univest Android App to receive SEBI-registered analyst research on Strides Pharma Science.
Frequently Asked Questions on Strides
What is the company PAT?
Ans. Strides reported PAT of Rs 129 crore up 50.0% YoY from Rs 86 crore in Q4 FY25. Results declared May 18, 2026. Full details from NSE/BSE regulatory filings. Verify all data before investing.
What is the company revenue?
Ans. The firm’s revenue from operations was Rs 1,323 crore for the quarter ended March 31, 2026. Track live on the Univest Screener.
When were Strides results announced?
Ans. The company results were announced on May 18, 2026, at the board meeting approving audited Q4 and FY26 financial statements for the year ended March 31, 2026.
Is Strides Pharma Science a good investment after Q4 FY26?
Ans. Investment decisions require individual assessment of fundamentals, valuation, sector dynamics, and personal risk tolerance. This article does not constitute investment advice. Consult a SEBI-registered financial advisor before investing.
Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice.
